A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Adicet Bio, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 416,294 shares of ACET stock, worth $457,923. This represents 0.0% of its overall portfolio holdings.

Number of Shares
416,294
Holding current value
$457,923
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 09, 2024

BUY
$1.76 - $3.45 $732,677 - $1.44 Million
416,294 New
416,294 $978,000
Q3 2022

Nov 10, 2022

BUY
$13.43 - $18.74 $1.2 Million - $1.67 Million
89,088 Added 252.44%
124,379 $1.77 Million
Q2 2022

Aug 05, 2022

BUY
$10.26 - $20.81 $3,580 - $7,262
349 Added 1.0%
35,291 $515,000
Q1 2022

May 12, 2022

BUY
$11.53 - $19.97 $88,804 - $153,808
7,702 Added 28.27%
34,942 $698,000
Q4 2021

Feb 10, 2022

BUY
$7.37 - $17.49 $200,758 - $476,427
27,240 New
27,240 $476,000

Others Institutions Holding ACET

About Adicet Bio, Inc.


  • Ticker ACET
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,030,800
  • Market Cap $44M
  • Description
  • Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...
More about ACET
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.